This MedLibrary.org supplementary page on Actinic keratosis is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
This article may require cleanup to meet Wikipedia's quality standards. Please improve this article if you can. (August 2008) |
| Actinic keratosis Classification and external resources |
|
| ICD-10 | L57.0 |
|---|---|
| ICD-9 | 702.0 |
Actinic keratosis (also called solar keratosis, or AK) is a premalignant condition of thick, scaly, or crusty patches of skin. It is more common in fair-skinned people, especially those who are frequently exposed to the sun, as it is usually accompanied by solar damage. Since some of these pre-cancers progress to squamous cell carcinoma, they should be treated.
When skin is exposed to the sun constantly, thick, scaly, or crusty bumps appear. The scaly or crusty part of the bump is dry and rough. The growths start out as flat scaly areas, and later grow into a tough, wart-like area.
An actinic keratosis site commonly ranges between 2 and 6 millimeters in size, and can be dark or light, tan, pink, red, a combination of all these, or have the same pigment as the surrounding skin. It may appear on any sun-exposed area, such as the face, ears, neck, scalp, chest, backs of hands, forearms, or lips.
Contents |
Prevention
Preventive measures recommended for AK are similar to those for skin cancer:
- Not staying in the sun for long periods of time without protection (e.g.:sunscreen, clothing, hats).
- Frequently applying powerful sunscreens with SPF ratings greater than 30 and that also block both UVA and UVB light.
- Wearing sun protective clothing such as hats, long-sleeved shirts, long skirts, or pants.
- Avoiding sun exposure during noon hours is very helpful because ultraviolet light is the most powerful at that time.
Diagnosis
Doctors can usually identify AK by doing a thorough examination. A biopsy may be necessary when the keratosis is large and/or thick, to make sure that the bump is a keratosis and not a skin cancer. Seborrheic keratoses are other bumps that appear in groups like the actinic keratosis but are not caused by sun exposure, and are not related to skin cancers. Seborrheic keratoses may be mistaken for an actinic keratosis.
Treatment
Various modalities are employed in the treatment of actinic keratosis:
- Diclofenac sodium 3% gel, e.g. Solaraze in Australia, contains nonsteroidal anti-inflammatory drug. Recommended duration of therapy is 60 to 90 days.
- Cryosurgery, e.g. with liquid nitrogen, by "freezing off" the AKs
- 5-fluorouracil (a chemotherapy agent): a cream that contains this medication causes AKs to become red and inflamed before they fall off
- Photodynamic therapy: this new therapy involves injecting a chemical into the bloodstream, which makes AKs more sensitive to any form of light.
- Laser, notably CO2 and Er:YAG lasers. A Laser resurfacing technique is often used with diffuse AKs.
- Electrocautery: burning off AKs with electricity
- Immunotherapy: topical treatment with imiquimod (Aldara), an immune enhancing agent
- Different forms of surgery
Regular follow-up after the treatment is advised by many doctors. The regular checks are to make sure no new bumps have developed and that old ones haven't become thicker.
Experimental treatments
In 2007, Australia biopharmaceutical company Clinuvel Pharmaceuticals Limited began clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name afamelanotide, formerly CUV1647)1 for actinic keratosis in organ transplant patients.23
Another Australian biopharmaceutical company Peplin 4 is also developing a topical treatment for actinic keratosis. Formed in 1998 they are currently developing PEP005, which is the first in a new class of compounds and which is derived from Euphorbia peplus, or E. peplus, a rapidly growing, readily-available plant, commonly referred to as petty spurge or radium weed. The sap of E. peplus has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, such as skin cancer and pre-cancerous skin lesions. The company has recently redomiciled to the USA and is about to enter phase III trials with PEP005.
External links
- American Academy of Dermatology
- American Osteopathic College of Dermatology
- National Library of Medicine and the National Institute of Health
- Actinic Keratosis photo library at Dermnet
- Medicinenet's article on Actinic Keratosis
- Information on Actinic Keratosis from The Skin Cancer Foundation
References
- ^ "World Health Organisation assigns CUV1647 generic name" (PDF). Clinuvel. 2008. http://www.clinuvel.com/resources/pdf/asx_announcements/2008/20080617WHOGenericName.pdf. Retrieved on 2008-06-17.
- ^ Clinuvel » Investors » FAQs
- ^ Australian Life Scientist - Tackling skin cancer in organ transplant patients
- ^ Peplin
- Abel EA (1989). "Cutaneous manifestations of immunosuppression in organ transplant recipients". J Am Acad Dermatol 21 (2 Pt 1): 167–79. PMID 2671063.
- Fitzpatrick TB (1988). "The validity and practicality of sun-reactive skin types I through VI". Arch Dermatol 124 (6): 869–71. doi:. PMID 3377516.
- Glogau RG (2000). "The risk of progression to invasive disease". J Am Acad Dermatol 42 (1 Pt 2): 23–4. doi:. PMID 10607353.
- Gordon D, Silverstone H. (1969). "The biologic effects of ultraviolet radiation". in Ubach F, editor. The Biologic Effects of Ultraviolet Radiation. Oxford (UK): Pergamon Press. p. 625.
- Lookingbill DP, Lookingbill GL, Leppard B (1995). "Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program". J Am Acad Dermatol 32 (4): 653–8. doi:. PMID 7896957.
- Marshall V (1974). "Premalignant and malignant skin tumours in immunosuppressed patients". Transplantation 17 (3): 272–5. doi:. PMID 4592184.
- Scotto J, Fears TR, Fraumeni JF. Incidence of nonmelanoma skin cancer in the United States. Publication No (NIH) 82-2433. Washington, DC: US Dept Health and Human Services; 1983.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 29 December 2008, at 21:50.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Actinic keratosis".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.